SCHEMBL6281043

SCHEMBL6281043

COc1ccc(S(=O)(=O)n2cc(/C(=N/NC(=N)N)C3CC3)c3ccccc32)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 8/20 0.51
PDE4A P27815 2/20 0.43
PDE4B Q07343 2/20 0.43
PDE4C Q08493 2/20 0.43
PDE4D Q08499 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALOX5 P09917 2/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PLK1 P53350 1/20 0.39
HCRTR1 O43613 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6281048 1.00 HTR6 (0.51) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6285419 0.89 HTR6 (0.48) HTR6MEN1KMT2AALOX5PLK1
SCHEMBL6285413 0.89 HTR6 (0.48) HTR6MEN1KMT2AALOX5PLK1
SCHEMBL6280992 0.89 HTR6 (0.44) HTR6SMN1; SMN2
SCHEMBL6280940 0.89 KCNH2 (0.47) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6280938 0.89 KCNH2 (0.47) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6280989 0.89 HTR6 (0.44) HTR6SMN1; SMN2
SCHEMBL6281979 0.86 TNFSF11 (0.44) HTR6MEN1KMT2AALOX5PLK1
SCHEMBL6281981 0.86 TNFSF11 (0.44) HTR6MEN1KMT2AALOX5PLK1
SCHEMBL6285571 0.86 HTR6 (0.55) HTR6PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885PDE4A 1140/4885PDE4B 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.